A Magnetic Bead-Based Sensor for the Quantification of Multiple Prostate Cancer Biomarkers

Novel biomarker assays and upgraded analytical tools are urgently needed to accurately discriminate benign prostatic hypertrophy (BPH) from prostate cancer (CaP). To address this unmet clinical need, we report a piezeoelectric/magnetic bead-based assay to quantitate prostate specific antigen (PSA; f...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2015-09, Vol.10 (9), p.e0139484
Main Authors: Jokerst, Jesse V, Chen, Zuxiong, Xu, Lingyun, Nolley, Rosalie, Chang, Edwin, Mitchell, Breeana, Brooks, James D, Gambhir, Sanjiv S
Format: Article
Language:English
Subjects:
Acid phosphatase
Acoustics
Aged
Antigens
Assaying
Benign
Biocompatibility
Biological markers
Biomarkers
Biomarkers, Tumor - blood
Biomedical materials
Biosensors
Cancer
Carbonic anhydrase
Carbonic anhydrases
Cytokines
Diagnosis
Diagnosis, Differential
DNA methylation
Female
Glycoproteins
Growth factors
Humans
Hypertrophy
Interleukin 6
Magnetite Nanoparticles
Male
Mass Screening
Metastasis
Middle Aged
Morphogenesis
Osteonectin
Patients
Phosphate esters
Physiological aspects
Prognosis
Prostate cancer
Prostatic Hyperplasia - diagnosis
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - therapy
Proteins
Systematic review
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Novel biomarker assays and upgraded analytical tools are urgently needed to accurately discriminate benign prostatic hypertrophy (BPH) from prostate cancer (CaP). To address this unmet clinical need, we report a piezeoelectric/magnetic bead-based assay to quantitate prostate specific antigen (PSA; free and total), prostatic acid phosphatase, carbonic anhydrase 1 (CA1), osteonectin, IL-6 soluble receptor (IL-6sr), and spondin-2. We used the sensor to measure these seven proteins in serum samples from 120 benign prostate hypertrophy patients and 100 Gleason score 6 and 7 CaP using serum samples previously collected and banked. The results were analyzed with receiver operator characteristic curve analysis. There were significant differences between BPH and CaP patients in the PSA, CA1, and spondin-2 assays. The highest AUC discrimination was achieved with a spondin-2 OR free/total PSA operation--the area under the curve was 0.84 with a p value below 10(-6). Some of these data seem to contradict previous reports and highlight the importance of sample selection and proper assay building in the development of biomarker measurement schemes. This bead-based system offers important advantages in assay building including low cost, high throughput, and rapid identification of an optimal matched antibody pair.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0139484